A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid Cancer
Authors' conclusion
While individual studies have demonstrated the importance of absorbed doses from Na[131I]I for differentiated thyroid cancer, no conclusive absorbed dose-effect relationship has been established in this review. A lack of standardization of dosimetry methodologies and follow-up criteria in the studies obscures the relationship. Large-scale observational prospective studies are required to determine the absorbed doses required for successful personalized treatments of patients with thyroid cancer with Na[131I]I.
Study context
- Population
- Patients with differentiated thyroid cancer treated with Na[131I]I (thyroid remnant ablation or metastatic lesions); studies reporting success rates and absorbed doses to targets, published before August 22, 202518 studies
- Outcome
- Proportion of patients achieving successful outcome (as defined in individual publications) in relation to absorbed doses delivered to targets
Methodological details3723 studies identified, 18 eligible; PubMed, Web of Science and OVID MEDLINE searched
- 3723 studies identified, 18 eligible; PubMed, Web of Science and OVID MEDLINE searched
Pooled result
As reported in the abstract
Success rate, thyroid remnant ablation
60% to 100%
Success rate, metastatic lesions
43-58%
Success rate, thyroid remnant absorbed dose ≥300 Gy
78% to 96%
Success rate, metastatic lesions receiving ≥80 Gy
46% to 98%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →